Trial reportBMC medical imaging2025
A CT-based intratumoral and peritumoral radiomics nomogram for postoperative recurrence risk stratification in localized clear cell renal cell carcinoma.
Trial report in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study.Annals of medicine · 2026Observational
- CT-Based Peritumoral and Perirenal Fat Radiomics in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Grade, Stage, and Adherent Perinephric Fat Prediction.Journal of clinical medicine · 2026Review
- Interpretable habitat radiomics based nomogram for predicting T790M mutation in non-small cell lung cancer with brain metastases.Quantitative imaging in medicine and surgery · 2026Article
- A multicenter multimodel habitat radiomics model for predicting immunotherapy response in advanced NSCLC.iScience · 2026Article
- Multiphase CT-Based Tumor and Peritumoral Radiomics for Characterization of Clear Cell Renal Cell Carcinoma.Journal of imaging informatics in medicine · 2026Article
- Multimodal deep learning for prediction of postoperative recurrence in clear cell renal cell carcinoma: a clinical-radiologic-pathologic approach.Frontiers in oncology · 2026Article
- Integration of multi-scale radiomics and deep learning for Ki-67 prediction in clear cell renal carcinoma.NPJ precision oncology · 2025Article
- Multicenter study of CT-based deep learning for predicting preoperative T staging and TNM staging in clear cell renal cell carcinoma.BMC cancer · 2025Article
- Multi-channel multiphase CT-based deep learning and radiomics fusion model for noninvasive pathological grading of clear cell renal cell carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aimed to develop and validate a computed tomography (CT)-based intratumoral and peritumoral radiomics nomogram to improve the stratification of postoperative recurrence risk in patients with localized clear cell renal cell carcinoma (ccRCC).
methodsThis two-center study included 447 patients with localized ccRCC. Patients from Center A were randomly split into a training set (n = 281) and an internal validation set (IVS) (n = 114) in a 7:3 ratio, while 52 patients from Center B formed the external validation set (EVS). Radiomics features from preoperative CT were obtained from the internal area of tumor (IAT), the internal and peritumoral areas of the tumor at 3 mm (IPAT 3 mm), and 5 mm (IPAT 5 mm). The least absolute shrinkage and selection operator (LASSO) Cox regression was used to construct a radiomics score to develop radiomics model (RM). A clinical model (CM) was also established using significant clinical factors. Furthermore, a fusion model (FM) was developed by integrating independent predictors from both clinical factors and the radiomics score (Radscore) through multivariate Cox proportional hazards regression. Model performance was assessed with Kaplan-Meier curves, time-dependent area under the curve (time-AUC), Harrell's concordance index (C-index), and decision curve analysis (DCA).
resultsCompared to both the IAT model and the IPAT 3 mm model, the IPAT 5 mm radiomics model demonstrated superior predictive performance for tumor recurrence (C-index: 0.924 vs. 0.915-0.923 in the IVS; 0.952 vs. 0.920-0.944 in the EVS). Therefore, the IPAT 5 mm radiomics score was incorporated into the development of the fusion model. The FM exhibited outstanding predictive accuracy, achieving a C-index of 0.938 in the IVS, significantly outperforming the CM (0.889, P = 0.03). Notably, in the EVS, the RM surpassed both the CM and FM (C-index: 0.952 vs. 0.904-0.940, P > 0.05). Furthermore, decision curve analysis indicated that the FM provided the highest net clinical benefit in the IVS, while both the FM and RM demonstrated substantially greater net benefit than the CM in the EVS.
conclusionsThe radiomics model and the fusion model, which integrate both intratumoral and peritumoral features, offer accurate prediction of recurrence risk in patients with localized ccRCC. These models have the potential to aid in personalized treatment planning, optimized surveillance strategies, and treatment strategies for patients with clear cell renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.